Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: Application to the evaluation of CYP2D6 drug interactions

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 783, Issue 1, 2003, Pages 213-219

  Lerena, Adrián ^a   Berecz, Roland ^a   Dorado, Pedro ^a   De la Garza, César Sanz ^a   Norberto, María Jesús ^a   Cáceres, Macarena ^a   Gutiérrez, José Ramón ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

9 Hydroxyrisperidone; CYP2D6; Risperidone

Indexed keywords

9 HYDROXY RISPERIDONE; 9-HYDROXY-RISPERIDONE; CYTOCHROME P450 2D6; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PYRIMIDINE DERIVATIVE; RISPERIDONE; ALPRAZOLAM; AMITRIPTYLINE; CHLORPROMAZINE; CLOMETHIAZOLE; CLOMIPRAMINE; CLORAZEPATE; FLUOXETINE; FLURAZEPAM; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LEVOMEPROMAZINE; LITHIUM; LORAZEPAM; MAPROTILINE; MIDAZOLAM; PALIPERIDONE; PERPHENAZINE; PHENOBARBITAL; PIMOZIDE; PINAZEPAM; SULPIRIDE; THIORIDAZINE; TIAPRIDE; TRIAZOLAM; TRIFLUOPERAZINE; UNINDEXED DRUG; ZOLPIDEM; ZOPICLONE;

ADULT; ARTICLE; BLOOD; DRUG INTERACTION; HUMAN; MALE; METABOLISM; REPRODUCIBILITY; BLOOD ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DETERMINATION; EXTRAPYRAMIDAL SYMPTOM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; ULTRAVIOLET RADIATION;

ADULT; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; HUMANS; ISOXAZOLES; MALE; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; RISPERIDONE;

CHEMICAL ANALYSIS; DRUG DOSAGE; DRUG INTERACTIONS; ENZYME INHIBITION; EXTRACTION; HIGH PRESSURE LIQUID CHROMATOGRAPHY; PATIENT TREATMENT; PHARMACOKINETICS; PLASMA APPLICATIONS; ULTRAVIOLET DETECTORS;

LIQUID-LIQUID EXTRACTION;

BIOMEDICAL ENGINEERING;

VIOLA (ANGIOSPERM);

EID: 0037419494     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-0232(02)00661-X     Document Type: Article

References (19)

1. Leysen J.E., Gommeren W., Eens A., de Chaffoy de Courcelles D., Stoof J.C., Janssen P.A. J. Pharmacol. Exp. Ther. 247:1988;661.
2. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., Labelle A., Beauclair L., Arnott W. J. Clin. Psychopharmacol. 13:1993;25.
3. Claus A., Bollen J., de Cuyper H., Eneman M., Malfroid M., Peuskens J., Heylen S. Acta Psychiatr. Scand. 85:1992;295.
4. Csernansky J.G., Mahmoud R., Brenner R. New Engl. J. Med. 346:2002;16.
5. Berecz R., Norberto M.J., Kellermann M., de la Rubia A., Degrell I., LLerena A. 10th European Symposium on Psychiatry, Psychiatric Epidemiology and Social Psychiatry, Budapest:2000.
6. Ereshefsky L., Lacombe S. Can. J. Psychiatry. 38:1993;S80.
7. Huang M.L., Van Peer A., Woestenborghs R., de Coster R., Heykants J., Janssen A.A.I., Zylicz Z., Visscher H.W., Jonkman J.H.G. Clin. Pharmacol. Ther. 54:1993;257.
8. LLerena A., Berecz R., de la Rubia A., Fernández-Salguero P., Dorado P. Ther. Drug Monit. 23:2001;616.
9. R. Berecz, A. LLerena, A. de la Rubia, J. Gómez, M. Kellermann, P. Dorado, I. Degrell, Pharmacopsychiatry (in press).
10. Price M.C., Hoffman D.W. Ther. Drug Monit. 19:1997;333.
11. Nagasaki T., Ohkubo T., Sugawara K., Yasui N., Furukori H., Kaneko S. J. Pharm. Biomed. Anal. 19:1999;595.
12. Kiivet R.A., LLerena A., Dahl M.L., Rootslane L., Sánchez Vega J., Eklundh T., Sjöqvist F. Br. J. Clin. Pharmacol. 40:1995;467.
13. Woestenborghs R., Lorreyne W., Van Rompaey F., Heykants J. J. Chromatogr. 583:1992;223.
14. Le Moing J.P., Edouard S., Levron J.C. J. Chromatogr. 614:1993;333.
15. Balant-Gorgia A.E., Gex-Fabry M., Genet C., Balant L.P. Ther. Drug Monit. 21:1999;105.
16. Olesen O.V., Linnet K. J. Chromatogr. B. 698:1997;209.
17. Avenoso A., Facciola G., Salemi M., Spina E. J. Chromatogr. B. 746:2000;173.
18. LLerena A., Cobaleda J., Martínez C., Benítez J. Eur. J. Drug Metab. Pharmacokinet. 21:1996;129.
19. WHO Collaborating Centre for Drug Statistics Methodology, ATC Index with DDDs, Oslo, Norway, 2000.